Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer

IMPORTANCE: Immune checkpoint inhibitors (ICIs) can elicit durable antitumor responses in patients with non–small cell lung cancer (NSCLC), but only 20% to 25% of patients respond to treatment. As important genes in the DNA damage response pathway, comutation in the tumor protein p53 (TP53) and atax...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Chen, Gang, Li, Jin, Huang, Ying-Ying, Li, Yi, Lin, Jing, Chen, Li-Zhu, Lu, Jian-Ping, Wang, Yu-Qi, Wang, Chang-Xi, Pan, Leong Kin, Xia, Xue-Feng, Yi, Xin, Chen, Chuan-Ben, Zheng, Xiong-Wei, Guo, Zeng-Qing, Pan, Jian-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755545/
https://www.ncbi.nlm.nih.gov/pubmed/31539077
http://dx.doi.org/10.1001/jamanetworkopen.2019.11895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755545/
https://www.ncbi.nlm.nih.gov/pubmed/31539077
http://dx.doi.org/10.1001/jamanetworkopen.2019.11895

Ejemplares similares